Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Related Articles by Review for PubMed (Select 14684455)

1.

Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.

Coyle JT, Tsai G, Goff D.

Ann N Y Acad Sci. 2003 Nov;1003:318-27. Review.

PMID:
14684455
2.

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Coyle JT, Tsai G.

Psychopharmacology (Berl). 2004 Jun;174(1):32-8. Epub 2003 Nov 25. Review.

PMID:
15205876
3.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Coyle JT.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.

PMID:
16773445
4.

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

Goff DC, Coyle JT.

Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.

PMID:
11532718
5.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
6.

Ionotropic glutamate receptors as therapeutic targets in schizophrenia.

Coyle JT, Tsai G, Goff DC.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):183-9. Review.

PMID:
12769626
7.

Glutamatergic mechanisms in schizophrenia.

Tsai G, Coyle JT.

Annu Rev Pharmacol Toxicol. 2002;42:165-79. Review.

PMID:
11807169
8.

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

Chaves C, Marque CR, Trzesniak C, Machado de Sousa JP, Zuardi AW, Crippa JA, Dursun SM, Hallak JE.

Braz J Med Biol Res. 2009 Nov;42(11):1002-14. doi: 10.1590/S0100-879X2009001100002. Review.

9.

The GABA-glutamate connection in schizophrenia: which is the proximate cause?

Coyle JT.

Biochem Pharmacol. 2004 Oct 15;68(8):1507-14. Review.

PMID:
15451393
10.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
11.

N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Millan MJ.

Psychopharmacology (Berl). 2005 Apr;179(1):30-53. Epub 2005 Mar 10. Review.

PMID:
15761697
12.
13.

Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Coyle JT.

Neurotox Res. 2006 Dec;10(3-4):221-33. Review.

PMID:
17197372
14.

The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.

Labrie V, Roder JC.

Neurosci Biobehav Rev. 2010 Mar;34(3):351-72. doi: 10.1016/j.neubiorev.2009.08.002. Epub 2009 Aug 18. Review.

PMID:
19695284
15.
16.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
18.

Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G.

Handb Exp Pharmacol. 2012;(213):267-95. doi: 10.1007/978-3-642-25758-2_10. Review.

PMID:
23027419
19.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk